Logotype for DuPont De Nemours Inc

DuPont De Nemours (DD) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for DuPont De Nemours Inc

Q4 2025 earnings summary

11 Apr, 2026

Executive summary

  • Fourth quarter and full-year 2025 results exceeded guidance, driven by strong operational discipline, productivity, and portfolio transformation, including the separation of Qnity Electronics and divestiture of the Aramids business.

  • Organic sales growth in FY25 was led by healthcare and water end-markets, offsetting construction softness.

  • Executed $500 million accelerated share repurchase in Q4 2025 and set clear medium-term financial targets.

  • Q4 2025 GAAP loss from continuing operations was $(108) million; full year GAAP income was $98 million.

  • Strategic priorities for 2026 focus on above-market organic growth, business system enhancement, and balanced capital allocation.

Financial highlights

  • Full-year 2025 net sales were $6.8 billion, up 2% year-over-year; operating EBITDA was $1.63 billion (margin 23.8%), up 6%; adjusted EPS was $1.68, up 16% year-over-year.

  • Q4 2025 net sales were $1.7 billion (flat YoY); operating EBITDA was $409 million (margin 24.2%), up 4%; adjusted EPS was $0.46, up 18%.

  • Transaction-adjusted free cash flow for FY25 was $689 million (98% conversion); Q4 2025 was $228 million (118% conversion).

  • Q4 2025 cash provided by operating activities was $87 million; full year was $560 million.

  • Significant non-recurring items in 2025 included $203 million in acquisition, integration, and separation costs, $151 million in restructuring charges, and $114 million in debt extinguishment losses.

Outlook and guidance

  • 2026 guidance: net sales $7.08–$7.14 billion, organic sales growth of ~3%, operating margin expansion of 60–80 basis points, adjusted EPS of $2.25–$2.30.

  • Free cash flow conversion expected to exceed 90%.

  • Q1 2026 guidance: net sales ~$1.67 billion, operating EBITDA ~$395 million, adjusted EPS ~$0.48.

  • Medium-term (FY25–FY28): 3–4% CAGR organic net sales, 150–200bps EBITDA margin improvement, 8–10% adjusted EPS CAGR.

  • Healthcare and Water expected to grow mid-single digits; Diversified Industrials to grow low single digits in 2026.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more